Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

AVE

Aventis (AVE)

Aventis New Ads
일자:
정렬 기준:
 검색 관련기사 보기:NYSE:AVE
일자시간출처헤드라인심볼기업
2004/10/1606:03PR Newswire (US)Rhone-Poulenc Overseas Limited Announces Redemption of All Outstanding Cumulative Guaranteed Preference Shares, Series ANYSE:AVEAventis New Ads
2004/10/0504:44PR Newswire (US)Aventis Ships 30 Million Doses of Influenza Vaccine to Health-Care ProvidersNYSE:AVEAventis New Ads
2004/09/2306:23PR Newswire (US)Advisory Panel Recommends FDA Licensure of Aventis' Menactra(TM) Vaccine for Protection Against Meningococcal DiseaseNYSE:AVEAventis New Ads
2004/09/2122:30PR Newswire (US)Aventis Named to List of Top 100 Companies for Working MothersLSE:AVE
2004/09/1616:00PR Newswire (US)The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual IdentityLSE:AVE
2004/09/1422:30PR Newswire (US)Coley Pharmaceutical Group Receives Payment From Aventis for Clinical Milestone in Collaboration on Allergic Respiratory DiseaseNYSE:AVEAventis New Ads
2004/08/1922:00PR Newswire (US)FDA Approves Taxotere(R) for the Treatment of Women with Early Stage Breast CancerNYSE:AVEAventis New Ads
2004/08/1200:39PR Newswire (US)Aventis Submits Application for FDA Licensure of ADACEL(TM) Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in AdoleNYSE:AVEAventis New Ads
2004/08/0609:02PR Newswire (US)Ventiv Health Announces Sales and Marketing Agreement with AventisNYSE:AVEAventis New Ads
2004/08/0403:58PR Newswire (US)FDA Approves Sculptra(TM) (Injectable Poly-L-Lactic Acid)NYSE:AVEAventis New Ads
2004/07/2904:31PR Newswire (US)Aventis Reports Second-Quarter and First-Half Results for 2004NYSE:AVEAventis New Ads
2004/07/2800:29PR Newswire (US)Aventis to Move Forward With Reissuance Process for Contested Lovenox PatentLSE:AVE
2004/07/0722:00PR Newswire (US)New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of Acute Coronary SyndromesLSE:AVE
2004/06/2323:50PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis Expiration Date of OffersLSE:AVE
2004/06/1500:43PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis DividendLSE:AVE
2004/06/0802:00PR Newswire (US)Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate CancerNYSE:AVEAventis New Ads
2004/06/0523:00PR Newswire (US)Investigators Report Taxotere(R) Offers Significant Survival Benefits for Head and Neck Cancer PatientsNYSE:AVEAventis New Ads
2004/06/0204:40PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis Expiration Date of OffersLSE:AVE
2004/05/2902:00PR Newswire (US)Genta and Aventis Announce Termination of Genasense(TM) Expanded Access Program in MelanomaNYSE:AVEAventis New Ads
2004/05/2716:00PR Newswire (US)Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine AgreementLSE:AVE
2004/05/2700:05PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004LSE:AVE
2004/05/2622:00PR Newswire (US)Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary SessionNYSE:AVEAventis New Ads
2004/05/2402:15PR Newswire (US)Data Show Once-Daily Alvesco(R) (ciclesonide) Has No Effect on HPA-Axis Function in Asthma PatientsLSE:AVE
2004/05/2402:15PR Newswire (US)Surveillance Study Finds Newly-Approved Antibiotic KETEK(R) (telithromycin) Tablets 99% Effective In Vitro Against StreptococcusLSE:AVE
2004/05/2004:39PR Newswire (US)Aventis Receives FDA Approval for Taxotere(R) in Prostate CancerNYSE:AVEAventis New Ads
2004/05/1822:01PR Newswire (US)Aventis Receives Priority Review Designation for the Registrational Application to Support the Use of Taxotere(R) in Women withLSE:AVE
2004/05/0600:12PR Newswire (US)Sanofi-Synthelabo's Offer for AventisLSE:AVE
2004/05/0404:52PR Newswire (US)FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced MelanomaNYSE:AVEAventis New Ads
2004/05/0104:55PR Newswire (US)Aventis Pasteur Statement on New Influenza Immunization Recommendations for Infants, Young Children and Their Close ContactsLSE:AVE
2004/04/3003:03PR Newswire (US)Aventis Reports First-Quarter Results for 2004LSE:AVE
 검색 관련기사 보기:NYSE:AVE